Last quarter (Q3 2021), Claritas Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Claritas Pharmaceuticals's net income was $―. See Claritas Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 20	Dec 19	Dec 18	Dec 17	Dec 16
Total Revenue	-	$ -1.22M	$ -2.22M	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	$ -1.22M	$ -2.22M	-	-	-
Operating Expense	$ -485.00K	$ -1.40M	$ -4.35M	$ 11.10M	$ 4.92M	$ 5.07M
Operating Income	$ 1.55M	-	-	$ -11.10M	$ -4.92M	$ -5.07M
Net Non Operating Interest Income Expense	$ -2.98M	$ 2.60M	$ 42.00K	$ -268.00K	$ -17.31M	$ -180.00K
Other Income Expense	$ -2.25M	$ 3.46M	$ 16.43M	$ 18.21M	$ -19.22M	$ -6.30M
Pretax Income	$ -5.68M	$ -674.00K	$ -14.25M	$ 6.84M	$ -31.86M	$ -11.55M
Tax Provision	$ -5.36M	$ -4.88M	$ -4.62M	$ -99.00K	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -2.96M	-	-	$ 6.93M	$ -31.86M	$ -11.55M
Basic EPS	$ -0.10	$ 0.01	$ -0.05	-	-	-
Diluted EPS	$ -0.10	-	-	-	-	-
Basic Average Shares	$ 668.21B	$ 533.82M	$ 448.81M	-	-	-
Diluted Average Shares	$ 54.86M	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -1.55M	-	-	$ 11.10M	$ 4.92M	$ 5.07M
Net Income From Continuing And Discontinued Operation	$ -4.04M	$ 4.21M	$ -9.63M	$ 6.93M	$ -31.86M	$ -11.55M
Normalized Income	$ 2.12M	$ 10.07M	$ 14.89M	$ -6.36M	$ -12.64M	$ -5.25M
Interest Expense	$ 39.00K	-	-	$ 153.00K	$ 16.03M	$ 0.00
EBIT	$ -4.91M	$ -403.00K	$ -13.55M	$ 6.99M	$ -15.83M	$ -11.55M
EBITDA	$ -4.91M	$ -403.00K	$ -13.55M	$ 6.99M	$ -15.83M	$ -11.54M

Currency in USD

Claritas Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing